An Easy "Insider” Biotech Trade for April

[] Insider buying is an important anomaly in the stock market. Today, I’m breaking down the movement of a stock called ORIC Pharmaceuticals and why the insider is buying the stock. [View in browser]( . Insider buying is an important anomaly in the stock market. Today, I’m breaking down the movement of a stock called ORIC Pharmaceuticals and why the insider is buying the stock. [View in browser]( . . [] [Havens Investment Letter] [] [Havens Investment Letter] [] [] [] Trading millionaire gives away his cell number Is this the end of monthly newsletters? Trading millionaire Rob Booker says so... Which is why he’s found a way to alert you of fast-moving stocks INSTANTLY. [It all starts by getting his private phone number here.]( [] --------------------------------------------------------------- [] Trading millionaire gives away his cell number Is this the end of monthly newsletters? Trading millionaire Rob Booker says so... Which is why he’s found a way to alert you of fast-moving stocks INSTANTLY. [It all starts by getting his private phone number here.]( [] --------------------------------------------------------------- [] [] An Easy “Insider” Biotech Trade for April [Garrett Pic]Dear Investor, On Friday, I talked a bit about the insider buying patterns. I also included a chart that showed you the Top 10 Insider purchases of the last ten days. Today, I want to update this chart because of one new entry… and what you might learn. As I’ve noted, we’re looking for CEOs and CFOs who have purchased at least $100,000 of their shares. In these cases, they are putting THEIR money on the line. Sometimes they’re buying more stock because they think it will go higher off recent gains. Other times, they’re buying because they believe the stock is undervalued after a recent selloff. The only thing that matters - as famous investor Peter Lynch once said -- “Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.” Today’s List We’re looking at Insider Buys based on SEC Form 4. These are the documents they must purchase when they buy or sell their stock. A quick scan of the data provides this list. [Top Stocks] Now, one stock sticks out. It wasn’t on the list Friday. Oric Pharmaceuticals (ORIC). The CEO bought 350,000 shares at an average of $4.92 on March 23. On Monday, shares rallied more than 16% on the news. It’s quite interesting because this stock has experienced dramatic insider selling over the last year. I’d argue that CEO Jacob Chacko was calling a bottom on the stock. The chart below shows that since March 2021, insiders have sold more than $32 million in stock. [ORIC insiders]( As I dig through those trades, I find that many shares sold at more than $25.00 per share. So, the stock has effectively fallen by 80% since many insiders sold shares. This is significant because of the value of the buy: More than $1.7 million. I’m interested because anything over $100,000 is significant in my research. So, that checks a box. That big downturn of more than 80% is also significant because it signals that the executive - based on the size of the stock - is willing to wager A LOT of his money on what he considers to be a bottom for ORIC shares. There’s one more thing that I want to see. Most people aren’t spending a lot of time looking at the options chains of these small stocks. This is a microcap stock with about $200 million market capitalization. So, large institutions aren’t going to be actively trading this stock. I looked out to the April, May, and later options chains. And I saw some small - barely noticeable - buying on the $5 call today. There was also some buying at the $7.50 level. April 14 is significant because it falls within a 30-day window of when I want to buy and trade biotech stocks with insider buying. But why is the speculation there with short-term options? There had to be a catalyst. I dug even deeper into potential events ahead of April 14, a period that suggests on the options chain that the stock might move up or down 22.3% based on volatility and the options straddle price. What I found is that ORIC Pharmaceuticals will be hosting multiple presentations at the 2022 American Association for Cancer Research (AACR). Three presentations over three days during the April 8 to 13 event. They are: ORIC-533 oral presentation and poster presentation to highlight potential of small molecule inhibitor of CD73 as a treatment for multiple myeloma ORIC-114 poster presentation to highlight compelling brain penetrant properties of an irreversible inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations PLK4 program poster presentation to introduce novel, highly selective inhibitors targeting a synthetic lethality approach as a potential treatment for breast cancer Now, I don’t know what most of this means, but I do like the idea of buying and holding the stock through the event. If one of these presentations or multiple presentations is very positive for the stock and a possible rebound, we could see stock upgrades. The worst case scenario, I buy the stock and set a 7% trailing stop. It’s possible that the stock trades higher ahead of the event and sells off on the day of presentation. Regardless, I’m content to manage my risk and take a chance on a CEO calling a bottom on this stock. We’ll continue to talk insiders this week. Enjoy your day, [Garrett Sig] Garrett {NAME} Chief Analyst, American Markets [] --------------------------------------------------------------- [] [] An Easy “Insider” Biotech Trade for April [Garrett Pic]Dear Investor, On Friday, I talked a bit about the insider buying patterns. I also included a chart that showed you the Top 10 Insider purchases of the last ten days. Today, I want to update this chart because of one new entry… and what you might learn. As I’ve noted, we’re looking for CEOs and CFOs who have purchased at least $100,000 of their shares. In these cases, they are putting THEIR money on the line. Sometimes they’re buying more stock because they think it will go higher off recent gains. Other times, they’re buying because they believe the stock is undervalued after a recent selloff. The only thing that matters - as famous investor Peter Lynch once said -- “Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.” Today’s List We’re looking at Insider Buys based on SEC Form 4. These are the documents they must purchase when they buy or sell their stock. A quick scan of the data provides this list. [Top Stocks] Now, one stock sticks out. It wasn’t on the list Friday. Oric Pharmaceuticals (ORIC). The CEO bought 350,000 shares at an average of $4.92 on March 23. On Monday, shares rallied more than 16% on the news. It’s quite interesting because this stock has experienced dramatic insider selling over the last year. I’d argue that CEO Jacob Chacko was calling a bottom on the stock. The chart below shows that since March 2021, insiders have sold more than $32 million in stock. [ORIC insiders]( As I dig through those trades, I find that many shares sold at more than $25.00 per share. So, the stock has effectively fallen by 80% since many insiders sold shares. This is significant because of the value of the buy: More than $1.7 million. I’m interested because anything over $100,000 is significant in my research. So, that checks a box. That big downturn of more than 80% is also significant because it signals that the executive - based on the size of the stock - is willing to wager A LOT of his money on what he considers to be a bottom for ORIC shares. There’s one more thing that I want to see. Most people aren’t spending a lot of time looking at the options chains of these small stocks. This is a microcap stock with about $200 million market capitalization. So, large institutions aren’t going to be actively trading this stock. I looked out to the April, May, and later options chains. And I saw some small - barely noticeable - buying on the $5 call today. There was also some buying at the $7.50 level. April 14 is significant because it falls within a 30-day window of when I want to buy and trade biotech stocks with insider buying. But why is the speculation there with short-term options? There had to be a catalyst. I dug even deeper into potential events ahead of April 14, a period that suggests on the options chain that the stock might move up or down 22.3% based on volatility and the options straddle price. What I found is that ORIC Pharmaceuticals will be hosting multiple presentations at the 2022 American Association for Cancer Research (AACR). Three presentations over three days during the April 8 to 13 event. They are: ORIC-533 oral presentation and poster presentation to highlight potential of small molecule inhibitor of CD73 as a treatment for multiple myeloma ORIC-114 poster presentation to highlight compelling brain penetrant properties of an irreversible inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations PLK4 program poster presentation to introduce novel, highly selective inhibitors targeting a synthetic lethality approach as a potential treatment for breast cancer Now, I don’t know what most of this means, but I do like the idea of buying and holding the stock through the event. If one of these presentations or multiple presentations is very positive for the stock and a possible rebound, we could see stock upgrades. The worst case scenario, I buy the stock and set a 7% trailing stop. It’s possible that the stock trades higher ahead of the event and sells off on the day of presentation. Regardless, I’m content to manage my risk and take a chance on a CEO calling a bottom on this stock. We’ll continue to talk insiders this week. Enjoy your day, [Garrett Sig] Garrett {NAME} Chief Analyst, American Markets --------------------------------------------------------------- [] Reclusive California Tech Wiz Reveals... the Perfect AAPL Trade [San Francisco bay]( [See the reveal of this remarkable system]( --------------------------------------------------------------- [] [] Reclusive California Tech Wiz Reveals... the Perfect AAPL Trade [San Francisco bay]( [See the reveal of this remarkable system]( --------------------------------------------------------------- [] [] [] Legendary stock picker has destroyed the newsletter industry for good Trading Legend Rob Booker has done it again. The 20-year veteran millionaire who navigated both bull and bear markets...is now turning the newsletter industry on its head. Giving the mainstream investors something that was previously off limits to them. You see, the ordinary investor is faced with two tough choices... They could spend years trying to figure things out like Rob did (Who really has the time for that)... Or they can get a financial newsletter to give them picks about once a month and hope things work out. Neither of those choices are very appealing. Which is why Rob has found a better way. He’s allowing anyone to get his real time stock ideas in while he analyzes the markets each day. These aren’t ideas he came up with out of thin air... These are his best trading opportunities that he trades alongside his followers. Once you’re on his contact list, all you need is a few minutes to act whenever he sends out a recommendation. The best part? He’s available to contact directly with any questions. Which is virtually unheard of in the newsletter industry these days. To join him, all you need to do is to take his phone number down. If you’re looking for a way to keep up with the market changes quickly, you need to check this out. Rob’s prepared a presentation explaining how it all works. [Get Rob’s private cell phone number here.]( --------------------------------------------------------------- [] [] [] Legendary stock picker has destroyed the newsletter industry for good Trading Legend Rob Booker has done it again. The 20-year veteran millionaire who navigated both bull and bear markets...is now turning the newsletter industry on its head. Giving the mainstream investors something that was previously off limits to them. You see, the ordinary investor is faced with two tough choices... They could spend years trying to figure things out like Rob did (Who really has the time for that)... Or they can get a financial newsletter to give them picks about once a month and hope things work out. Neither of those choices are very appealing. Which is why Rob has found a better way. He’s allowing anyone to get his real time stock ideas in while he analyzes the markets each day. These aren’t ideas he came up with out of thin air... These are his best trading opportunities that he trades alongside his followers. Once you’re on his contact list, all you need is a few minutes to act whenever he sends out a recommendation. The best part? He’s available to contact directly with any questions. Which is virtually unheard of in the newsletter industry these days. To join him, all you need to do is to take his phone number down. If you’re looking for a way to keep up with the market changes quickly, you need to check this out. Rob’s prepared a presentation explaining how it all works. [Get Rob’s private cell phone number here.]( --------------------------------------------------------------- [] [] Article Recap - [An Easy “Insider” Biotech Trade for April](#i572731) - [Legendary stock picker has destroyed the newsletter industry for good](#155245) --------------------------------------------------------------- [] Article Recap - [An Easy “Insider” Biotech Trade for April](#i572731) - [Legendary stock picker has destroyed the newsletter industry for good](#155245) --------------------------------------------------------------- [] © 2022 Godesburg Financial Publishing, Inc. DISCLAIMER: COMMUNICATIONS FROM GODESBURG FINANCIAL PUBLISHING (GFP) ARE FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY – NOT INVESTMENT ADVICE: GFP and all the services it offers are for educational and informational purposes only and should NOT be understood to be securities-related offers or solicitations. None of GFP’s communications should be considered or used as personalized investment advice. GFP recommends that you speak with a licensed professional before making any investment decision. RESULTS PRESENTED ARE NOT NECCESSARILY TYPICAL OR VERIFIED: GFP communications may include information regarding the historical trading performance of gurus in their services (all verified by a third party), as well as testimonials of non-employees depicting profitable investments and trades that are believed to be true based on the representations of the persons providing the testimonial of their own free will. Please be aware that the claims regarding investing or trading results of non-employees are not tracked by GFP nor can they be verified. As always, past performance is not necessarily indicative of future results. Therefore, results presented in this email should NOT be considered TYPICAL. Actual results can and will vary based on everything from experience, ability, risk mitigation practices, and market volatility... to the amount of money exposed in the investment or trade. Investing and trading are speculative and carry serious risk. You may lose some, all - or possibly more - than your original investment or trade. GODESBURG FINANCIAL PUBLISHING IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER: GFP, including its owners and employees, are NOT registered as securities broker-dealers, brokers, or any sort of registered investment advisors with the U.S. Securities and Exchange Commission, any state securities regulatory authorities, or any self-regulatory organizations. GODESBURG FINANCIAL PUBLISHING EMPLOYEES MAY HOLD SECURITIES DISCUSSED: If a writer holds any securities in a communication, it will be disclosed along with the information on the potential investment or trade. HIR, its owners or employees, have not been - or ever will be - paid by the issuer of a security mentioned in our services or communications. GFP, its owners and employees are paid entirely or in part from commissions based on sales of their services to subscribers. For more information, please visit [our disclaimer page here.]( Sent to: {EMAIL} [Unsubscribe]( Godesburg Financial Publishing Inc., 251 Little Falls Drive, Wilmington, DE 19808, United States [] © 2022 Godesburg Financial Publishing, Inc. DISCLAIMER: COMMUNICATIONS FROM GODESBURG FINANCIAL PUBLISHING (GFP) ARE FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY – NOT INVESTMENT ADVICE: GFP and all the services it offers are for educational and informational purposes only and should NOT be understood to be securities-related offers or solicitations. None of GFP’s communications should be considered or used as personalized investment advice. GFP recommends that you speak with a licensed professional before making any investment decision. RESULTS PRESENTED ARE NOT NECCESSARILY TYPICAL OR VERIFIED: GFP communications may include information regarding the historical trading performance of gurus in their services (all verified by a third party), as well as testimonials of non-employees depicting profitable investments and trades that are believed to be true based on the representations of the persons providing the testimonial of their own free will. Please be aware that the claims regarding investing or trading results of non-employees are not tracked by GFP nor can they be verified. As always, past performance is not necessarily indicative of future results. Therefore, results presented in this email should NOT be considered TYPICAL. Actual results can and will vary based on everything from experience, ability, risk mitigation practices, and market volatility... to the amount of money exposed in the investment or trade. Investing and trading are speculative and carry serious risk. You may lose some, all - or possibly more - than your original investment or trade. GODESBURG FINANCIAL PUBLISHING IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER: GFP, including its owners and employees, are NOT registered as securities broker-dealers, brokers, or any sort of registered investment advisors with the U.S. Securities and Exchange Commission, any state securities regulatory authorities, or any self-regulatory organizations. GODESBURG FINANCIAL PUBLISHING EMPLOYEES MAY HOLD SECURITIES DISCUSSED: If a writer holds any securities in a communication, it will be disclosed along with the information on the potential investment or trade. HIR, its owners or employees, have not been - or ever will be - paid by the issuer of a security mentioned in our services or communications. GFP, its owners and employees are paid entirely or in part from commissions based on sales of their services to subscribers. For more information, please visit [our disclaimer page here.]( Sent to: {EMAIL} [Unsubscribe]( Godesburg Financial Publishing Inc., 251 Little Falls Drive, Wilmington, DE 19808, United States